NASDAQ:AUTL Autolus Therapeutics Q3 2026 Earnings Date & Estimates $1.52 -0.06 (-3.80%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$1.52 0.00 (0.00%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Autolus Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Autolus Therapeutics in Q3 2026Autolus Therapeutics is expected to post earnings of -$0.21 per share on revenue of $39.54 million. In the same quarter a year earlier Autolus Therapeutics reported -$0.30 per share on revenue of $21.19 million. Autolus Therapeutics last reported on August 11, 2026, posting -$0.15 per share and beating the -$0.21 consensus estimate. Autolus Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.21Expected Revenue$39.54 millionPrior-Year EPS-$0.30Prior-Year Revenue$21.19 millionExpected Revenue Growth+86.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.15 (Beat by +$0.06)Last Quarter Revenue$45.69 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Autolus Therapeutics Q3 2026 Earnings FAQ When does Autolus Therapeutics report Q3 2026 earnings? Autolus Therapeutics (NASDAQ:AUTL) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Autolus Therapeutics' Q3 2026 earnings call? Autolus Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Autolus Therapeutics? Analysts expect Autolus Therapeutics to post earnings of -$0.21 per share for Q3 2026. How much revenue is Autolus Therapeutics expected to report? The consensus revenue estimate for Autolus Therapeutics is $39.54 million for Q3 2026. Autolus Therapeutics Earnings HeadlinesComparing Autolus Therapeutics (NASDAQ:AUTL) and Tonix Pharmaceuticals (NASDAQ:TNXP)October 31 at 2:15 AM | americanbankingnews.comAutolus Therapeutics: Cheap On Sales, Still Far From BreakevenOctober 27, 2026 | seekingalpha.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.October 31 at 1:00 AM | Monument Traders Alliance (Ad)Autolus Therapeutics: Key Questions For The Near TermOctober 27, 2026 | seekingalpha.comAutolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026October 26, 2026 | globenewswire.comAutolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026October 5, 2026 | globenewswire.comSee More Autolus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Autolus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autolus Therapeutics and other key companies, straight to your email. Email Address About Autolus TherapeuticsAutolus Therapeutics (NASDAQ:AUTL) plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety. Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus also maintains a development pipeline of investigational T-cell therapies targeting blood cancers and solid tumors, including programs based on its proprietary T-cell programming platform. Autolus was founded in 2014 and is headquartered in London, with operations supporting research, development and commercialization in the United Kingdom and the United States. The company is led by Chief Executive Officer Christian Itin.View Autolus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's WhyStarbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?Breaching the Valuation: The Real Reason Fortinet Dropped Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
